ライフサイエンスコーパス: doubling time

1 oli under moderate growth conditions (67 min doubling time).

2 eters (such as clinical stage and lymphocyte doubling time).

3 1944 cell lines significantly decreased cell doubling time.

4 te blood cell counts, and shorter lymphocyte doubling time.

5 ss than 10 microM retarded growth within one doubling time.

6 , 11q22/17p13 deletion, and short lymphocyte doubling time.

7 py, continued PSA progression, and rapid PSA doubling time.

8 cells for time periods greater than the cell doubling time.

9 ical recurrence as prostate-specific antigen doubling time.

10 mor cell proliferation as determined by cell doubling time.

11 vels in E. coli are constant irrespective of doubling time.

12 ion of FtsZ remains constant irrespective of doubling time.

13 ng structures divided and grew with a normal doubling time.

14 n burden and lifespan, as well as population doubling time.

15 of metastatic disease, PSA velocity, or PSA doubling time.

16 8 years, similar to the all-cause mortality doubling time.

17 strongly associated with increased epidemic doubling time.

18 strains, which corresponds with the cellular doubling time.

19 -induced DSB and greatly improved population-doubling times.

20 ng six cytokeratins, and inhibited cell line doubling times.

21 d was suppressed for cell types with shorter doubling times.

22 n oscillator in the suprachiasmatic nucleus (doubling time = 0.5-1.3 h).

23 with mice without Treg-cell ablation (tumor doubling time, 16.7 vs 4.9 days, respectively; P = .02).

24 ynechococcus 2973) has the shortest reported doubling time (2.1 h) among cyanobacteria, making it a p

25 ures of the cohort included short median PSA doubling time (2.3 mo) and extensive prior treatment, in

26 ures of the cohort included short median PSA doubling time (2.3 months) and extensive prior treatment

27 jected compared with untreated tumors (tumor doubling time 3.1 and 10.6 d, respectively; p < 0.01), w

28 gnificant association could be found for PSA doubling time (82.7%, 96.2%, and 90.7% in >6, 4-6, and <

29 th slow rates of disease progression (median doubling time: 84 days, 95% uncertainty range 62-104) an

30 ound occurs early relative to the viral load doubling time, a model with multiple successful reactiva

31 t of control was achieved without population doubling time acceleration.

32 In modeling simulations, tumor cell doubling time, administered antibody, antibody specific-

33 NC cells exhibited a nearly fourfold faster doubling time after populating the branchial arches.

34 display a higher growth fraction and shorter doubling time, along with a shorter interval to generati

35 Differences in endpoint survival and tumor doubling time among the groups were highly significant (

36 We estimated mean epidemic doubling time, an important measure of epidemic growth,

37 We performed volumetric and doubling time analysis on 63 non-small cell lung cancers

38 se in S-phase fraction, a 10-15% decrease in doubling time and a 20% increase in colony formation com

39 cycle defects, including reduced population-doubling time and a delay in cell cycle reentry from qui

40 was stratified by prostate-specific antigen doubling time and baseline use of a bone-targeting agent

41 rence, there was a tendency toward increased doubling time and decreased percentage of MCM2 in the ce

42 aHP1(Hsbeta) showed a decrease in population doubling time and decreased sensitivity to IR compared t

43 An increase in the cell population doubling time and higher sensitivity to cell killing by

44 s pT58 levels, leading to an increase in the doubling time and impairment of cell cycle progression.

45 s and cell-cycle arrest, elevating the tumor doubling time and increasing mouse survival.

46 s individual-level dynamics-including a long doubling time and low probability of immune recovery-tha

47 nes correlated with functional phenotypes of doubling time and oxidative stress.

48 rage-independent growth, shortens population-doubling time and reduces contact inhibition.

49 for Ng is challenged by the pathogen's slow doubling time and the lack of methods to quickly quantif

50 Between doubling times and (18)F-DOPA PET positivity, no signifi

51 antisense approaches, resulted in prolonged doubling times and decreased anchorage-independent growt

52 osomal HR HPV genomes had shorter population doubling times and formed dysplastic stratified epitheli

53 Additionally, we provide measurements of doubling times and in-vivo metabolic fluxes through the

54 Doubling times and radial growth rates were examined und

55 GF-C expression and COX2 expression, shorter doubling times and reduced expression of angiopoietin 2

56 ty increased for cell types with the longest doubling times and was suppressed for cell types with sh

57 ility to grow in Fe(III) citrate medium with doubling times and yields that were ca. 145% and 70% of

58 ation of simulated aggressive (2-month tumor doubling time) and nonaggressive (18-month tumor doublin

59 ase progression, defined in terms of the PSA doubling time, and "upgrading" at repeat biopsy.

60 imated cell energy consumption by population doubling time, and cell survival and growth by succinate

61 The telomere-telomerase axis, population-doubling time, and insulin-like growth factor-1 receptor

62 In postsurgical patients, PSA, PSA doubling time, and PSA velocity correlated with PET resu

63 (18)F-DCFPyL PET/CT correlates with PSA, PSA doubling time, and PSA velocity, suggesting it may have

64 on the DNA copy number, gene location, cell doubling time, and the rates of transcription and degrad

65 tomatic presentation of tumors, tumor volume doubling time, and time between screenings were examined

66 r cell cycle time ( approximately 13 h) than doubling time ( approximately 35 h), suggesting that the

67 n, absolute pre-RT PSA level, and pre-RT PSA doubling time are emerging as important determinants of

68 to 1.51) for Sierra Leone; the corresponding doubling times are 15.7 days (95% CI, 12.9 to 20.3) for

69 alcitonin and carcinoembryonic antigen (CEA) doubling times are currently the most reliable markers f

70 antigen (PSA) dynamics (PSA velocity and PSA doubling time) are widely advocated as useful prognostic

71 Labeled cells showed normal morphology and doubling time as control cells.

72 Adult NC cells exhibited longer doubling times as compared to neonatal NC cells, but sho

73 The results from doubling time assay suggested that PTPgamma is capable o

74 passaging ability, cycling quiescence, long doubling time, asymmetric division, high metastatic and

75 Population doubling time averaged 27 hours in mCSCs and vCSCs; 5x10

76 The doubling time based on a Poisson regression was 5.5 year

77 Our model makes accurate estimates of doubling times based on an optimized compartment shell p

78 pted in the fast-growth regime, that is, for doubling times below 1 h, extension of these dogmas to t

79 ells renew and proliferate in culture with a doubling time between 3 and 4 days.

80 There was considerable overlap in doubling time between histologic subtypes.

81 showed significantly increasing trends with doubling times between 5.5 and 13 years.

82 were evaluated using an Alamar Blue reagent, doubling time calculations and quantitative TEM, respect

83 rapidly in rich medium at 37 degrees C, the doubling time can be as short as ~20 min and the average

84 Volume-doubling time can only indicate overdiagnosis and was es

85 ns on population-level characteristics, like doubling time, carrying capacity, and growth rate.

86 but are growing and dividing, albeit with a doubling time close to 4 days.

87 degrees C), individual cell lines displayed doubling times consistent with endothelial cells possess

88 We determined whether the BCR-ABL1 doubling time could distinguish nonadherence from resist

89 bor null mutations in MELK exhibit wild-type doubling times, cytokinesis, and anchorage-independent g

90 nificantly with WBMTB on (18)F-DOPA PET, but doubling times did not.

91 ind excellent agreement between the observed doubling-time distribution and the predicted universal d

92 a combination of data representing cellular doubling time, DNA content, chromosome number, metacentr

93 ST PSA nadir (pCox < .0001), the pre-AST PSA doubling time (DT) (pCox = .002), PSA level (P = .0001),

94 Reciprocal of doubling time (DT) (RDT) was calculated.

95 e cancer and prostate-specific antigen (PSA) doubling time (DT) of less than 12 months were randomly

96 eoperative predictors of a postoperative PSA doubling time (DT) of less than 3 months and more than 1

97 Median PSA doubling time (DT) was 2.5 years for those who underwent

98 Doubling time (DT) was calculated by using the volume an

99 the first and last study to calculate tumor doubling time (DT).

100 The population doubling times (DT) of sham-irradiated cells varied from

101 Doubling times (DT) were divided into three groups: rapi

102 alcitonin and carcinoembryonic antigen (CEA) doubling times (DTs).

103 New data show that prostate-specific antigen doubling time during prostate-specific antigen recurrenc

104 Doubling time estimates, dose response curve regression,

105 ession total serum prostate-specific antigen doubling times, failure to respond to salvage local radi

106 led MTHF depended upon a combination of cell doubling time, folate receptor status, S phase percentag

107 A short doubling time for a patient in CP should raise the suspi

108 Median tumor doubling time for controls was 5.5 d (interquartile rang

109 l wall 14000 times in the course of a single doubling time for E. coli.

110 This justifies the use of volume doubling time for the growth assessment of these nodules

111 The corresponding doubling times for BTBPE are about 5 and 7 years in Lake

112 Mean endpoint survival and tumor doubling times for the three RF levels (0, 70 degrees C,

113 in tumor weight, and the extension of tumor-doubling time from 8.5 +/- 1.38 to 12 +/- 1.07 days as c

114 2/25) of (18)F-FDG PET-negative patients had doubling times greater than 24 mo (P < 0.001).

115 Winning clones exhibited shorter doubling times, greater maximum culture densities, and a

116 The initial viral doubling time had a median of 0.65 days with an interqua

117 The study of tumor marker doubling times has guided the extent of surgery and lymp

118 illion peptidoglycan strands within a single doubling time (i.e., generation) of E. coli.

119 for in vitro growth correlated directly with doubling time in blood, in the case of B-CLL with Ig H c

120 ge degree of GDGT cyclization increases with doubling time in continuous cultures of the thermoacidop

121 variable but significant average increase in doubling time in lymphoblastoid cell lines derived from

122 2 STI arms had a significantly longer median doubling time in the period of the initial rise of viral

123 Differences in endpoint survival and tumor doubling time in the six groups were highly significant

124 The epidemic doubling time in the United States was 2.68 days (95% co

125 evidence that calculation of PSA velocity or doubling time in untreated patients provides predictive

126 ET or (18)F-DOPA PET with calcitonin and CEA doubling times in 47 MTC patients.

127 nt/nearly identical increase in the ratio of doubling times in DMDM medium in the presence/absence of

128 st recent literature on volumetry and volume doubling times in lung nodule management, outlining thei

129 Cancer cell doubling times in patient tumors are longer than in cult

130 e diffusion of EF-Tu in E. coli growing with doubling times in the range 62-190 min at 37 degrees C d

131 Despite very different doubling times in vitro, all three establish similar lev

132 The doubling time (in hours) of HCECs from the central area

133 onin and carcinoembryonic antigen (and their doubling times), in addition to comprehensive imaging to

134 Tumor-doubling time increased from 3.5 +/- 0.5 d to 5.2 +/- 1.

135 t, with a lower-dose inoculum, the bacterial doubling time increased to 56 min and the S. pneumoniae

136 a number of oncogenic properties: decreased doubling times, increased clonogenicity and viability, f

137 The population doubling time is approximately 4 days.

138 lure exceeds 3 years, and post-treatment PSA doubling time is at least 12 months, and who did not hav

139 The sharp change in doubling time is followed by a sharp change in phenotypi

140 Optimal doubling time is obtained by maintaining a sufficiently

141 stage disease or a prostate-specific antigen doubling time less than 12 months) may also receive bene

142 aHR], 1.72; 95% CI, 1.17-2.52; P = .01), PSA doubling time less than 9 months (aHR, 2.06; 95% CI, 1.2

143 lating efficiency, elongated cell population doubling time, lower clonogenic fraction in soft agar, a

144 d high-risk features (Gleason score > 7, PSA doubling time < 10 mo, or PSA > 1.0 ng/mL) with negative

145 A failure < 3 years and a post-treatment PSA doubling time < 3 months place a man at increased risk f

146 e-specific antigen [PSA] >/=8.0 mug/L or PSA doubling time </=10.0 months, or both) were enrolled at

147 gen [PSA] failure, PSA nadir >0.5 ng/mL, PSA doubling time <9 months, and interval to PSA failure <30

148 dynamically on the basis of two factors: PSA doubling time (</= 3 v > 3 months) and nodal versus non-

149 ize clones using whole-genome sequencing and doubling time measurements.

150 Long doubling times observed with mutations in CP allow time

151 Longer doubling times occurred for patients with mutations who

152 Short doubling times occurred with blast crisis (median, 9.0 d

153 rate of any known organism, with a reported doubling time of <10 min.

154 the basis of conventional imaging and a PSA doubling time of <=10 months) who were continuing to rec

155 the sole terminal electron acceptor, with a doubling time of 1 day.

156 from which biosulfur showed fastest growth (doubling time of 1.9 days), followed by colloidal, chemi

157 41% (95% CI, 31% to 51%) who also had a PSA doubling time of 10 months or less or poorly differentia

158 state cancer and a prostate-specific antigen doubling time of 10 months or less.

159 replication, with an estimated S. pneumoniae doubling time of 16 min.

160 importations from Hubei, corresponding to a doubling time of 2.8 days, combined with a slower growth

161 The new isolate has a doubling time of 2.8 h at 1% CO(2), 1000 umole photons.m

162 hase fraction by flow cytometry and a faster doubling time of 24-36 h compared with 72 h for parental

163 rred over a median of 7 weeks, with a median doubling time of 3 days.

164 ting enzyme of the mevalonate pathway, had a doubling time of 4 h under anaerobic conditions, in cont

165 , have a high self-renewal capability with a doubling time of 46 h.

166 as characterised by fast exponential growth (doubling time of 5-7 days) and fast spatial expansion (4

167 n receptor, and an unusually rapid growth (a doubling time of 6.5 days) for prostate cancer xenograft

168 d a maximum growth rate of 0.078 h(-1) and a doubling time of 9 h, and the DeltaG of the reaction ran

169 g thymic glucose metabolism, with a mean SUV doubling time of 9.0 wk (range, 6.0-17.5 wk).

170 f pharmaceuticals in sediment cores showed a doubling time of 9.2 years.

171 Amplification occurs with a doubling time of about 1 hour and can be continued indef

172 cking 46 N-terminal amino acids, which had a doubling time of about 3 h.

173 nd from 10 degrees C to 35 degrees C, with a doubling time of approximately 15 h at pH 6.3 and 22 deg

174 ll line, ID6, had a normal karyotype, a cell doubling time of approximately 17 h, and has been mainta

175 ared similar morphology and had a population doubling time of approximately 2 days.

176 of genome sequencing was established, with a doubling time of approximately 20 months for bacteria an

177 ties (approximately 1 x 10(8) per ml) with a doubling time of approximately 24 h.

178 s in a serum-free, defined medium and with a doubling time of approximately 36 h.

179 ly under photoautotrophic conditions, with a doubling time of approximately 40 h, and had severely re

180 cells can be expanded without feeders with a doubling time of around 24 h.

181 also inhibits colony formation and increases doubling time of colon tumor cells.

182 For T > 30 degrees C, the doubling time of E. coli increases exponentially with pr

183 The doubling time of ENF-resistant viruses was highly correl

184 study was a prostate-specific antigen (PSA) doubling time of less than 12 mo after initial treatment

185 ffered for a prostate-specific antigen (PSA) doubling time of less than 3 years, Gleason score progre

186 ned as PSA level of 10 ng/mL or greater, PSA doubling time of less than 3 years, or upgrading (define

187 ave grown, and 8.3% (66 of 794) had a volume doubling time of less than 400 days.

188 ited to men with a prostate-specific antigen doubling time of less than 6 months and remained after a

189 l among men with a prostate-specific antigen doubling time of less than 6 months, independent of othe

190 Because of the long doubling time of M. leprae (13 days) and the delayed ons

191 We have observed retarded growth and longer doubling time of MBP-1 knockdown PC3 cells as compared w

192 posure times much shorter than the 1- to 2-h doubling time of Ng?

193 The doubling time of non-small lung cell cancer lines, which

194 The median volume doubling time of noninvasive adenocarcinoma was signific

195 cells that divide less than once every year (doubling time of over 450 days).

196 cage readily infect each other, and that the doubling time of P. carinii in vivo is approximately 3 d

197 ys are fundamentally constrained in speed by doubling time of the pathogen, and genotypic assays are

198 dependence of the solutions is scaled to the doubling time of the prostate specific antigen (PSADT) b

199 The doubling time of the slowly cycling population was estim

200 erobic conditions, in contrast to the 45 min doubling time of the wild type.

201 The doubling time of tumours in mice treated with MLN0518 wa

202 state cancer and a prostate-specific antigen doubling time of up to 10 months were randomly assigned

203 y the low transformation efficiency and long doubling time of yeast relative to bacteria.

204 h is the case for this system and provides a doubling time of ~20 min.

205 slow-cycling melanoma cells that cycle with doubling times of >4 weeks within the rapidly proliferat

206 tic growth coalescent models reveal epidemic doubling times of 0.86 and 1.12 years for the US and Car

207 over time at the rural and remote sites with doubling times of 2.2 and 3.7 years, respectively.

208 y colloidal, chemical and sublimated sulfur (doubling times of 2.2, 2.5, and 3.6 days, respectively).

209 or phase concentrations were increasing with doubling times of 5-10 years at Sturgeon Point, Sleeping

210 rapidly over the first 4 h of infection with doubling times of approximately 15-28 min.

211 We quantified doubling times of both Gram positive ( Staphylococcus au

212 Doubling times of cells from each area were compared.

213 of cell cycle progression revealed shortened doubling times of Hyal1-expressing cells.

214 We calculate the distribution of doubling times of such optimally scheduled self-replicat

215 n were rapidly increasing at most sites with doubling times of ~2 years.

216 lues are equivalent to average intermitotic (doubling) times of 15 and 48 d, respectively.

217 hP) showed an apparent temporal trend with a doubling-time of 11 months (p = 0.044).

218 d correlation of specific microRNAs with the doubling-time of cells or their radiation sensitivity.

219 st, including an approximately 12 h delay in doubling time on exposure to 25 mg/L CdTe QD ( approxima

220 t active mutant ribosomes are robust, with a doubling time only 14% longer than wild-type.

221 of alpha (32)P-dTTP relative to either cell doubling time or alpha (32)P-dCTP incorporation was incr

222 tic disease (rapid prostate-specific antigen doubling time or velocity) but otherwise is not suggeste

223 g exponential growth with a decreased volume doubling time, or 2) Gompertz-repopulation using the gra

224 aging, such as progressive changes in size, doubling time, or sibling health.

225 prostatectomy Gleason grade (P < .001), PSA doubling time (P < .001), surgical margins (P < .001), a

226 with stage of disease (P < .001), lymphocyte doubling time (P = .01), V(H) gene mutation status (P <

227 erum deprivation after which cell population doubling time, proliferation fraction, and cell cycle pe

228 te-specific antigen (PSA), PSA velocity, PSA doubling time, proPSA, PCA3, TMPRSS2-ERG.

229 to metastasis, including post-treatment PSA doubling time (PSA-DT), Gleason score, and interval to P

230 In a multivariate analysis, PSA doubling time (PSA-DT; P < .001), the clinical T stage (

231 fore the BS (trigger PSA), PSA kinetics (PSA doubling time, PSA slope, and PSA velocity), and time fr

232 t, Gleason score, NCCN stage, PSA level, PSA doubling time, PSA velocity, and time between initial tr

233 hensive Cancer Network stage, PSA level, PSA doubling time, PSA velocity, and time between initial tr

234 cific antigen (PSA) >/= 8.0 ng/mL and/or PSA doubling time (PSADT) </= 10.0 months.

235 gins (HR, 1.9; 95% CI, 1.4-2.5; P<.001), PSA doubling time (PSADT) of 10 months or less (HR, 1.7; 95%

236 whether pretreatment PSA velocity (PSAV) or doubling time (PSADT) predicted outcome in men undergoin

237 that postoperative prostate-specific antigen doubling time (PSADT) was associated with risk of prosta

238 At multivariate analysis, PSA, PSA doubling time (PSAdt), and ongoing ADT were significant

239 apse and 75% (P < 0.001) cases for short PSA doubling time (PSADT, <4 months).

240 tivity correlated positively with population doubling time (R(2) = 0.91 for PAC, 0.76 for QTH, 0.68 f

241 on influences telomere stability, population doubling time, radioresistance, and tumorigenicity in a

242 ither grown under a variety of conditions at doubling times ranging from 0.1 to 2.2 doublings per hou

243 th varying depleted levels of YlqF, yielding doubling times ranging from 38 min to 150 min, all displ

244 rom metabolically synchronized cultures with doubling times ranging from 5 to 14 h.

245 ) size control is effected by changes in the doubling time, rather than in the single-cell elongation

246 These cell lines showed elongated cell doubling time, reduced anchorage-independent growth in s

247 ecreased EGFR expression and increased tumor doubling time, relative to controls receiving EGFR siRNA

248 The doubling time revealed major differences in kinetics acc

249 nkov) telescopes, revealing variability with doubling time scales faster than 4.8 min.

250 MCT-1), that has been shown to decrease cell-doubling time, shorten the duration of G(1) transit time

251 pecific cell type used and on its population-doubling times so that the required numbers of cells are

252 and may be associated with an increased PSA doubling time suggests that a multi-institutional phase

253 higher numbers when cultured at a cell mass doubling time (t(d)) of 1.8 h than at a slower t(d) of 1

254 erotype, grown in a chemostat at a cell mass-doubling time (t(d)) of 1.8 h with oxygen invaded human

255 ing permits the calculation of the potential doubling time (T(pot)) of the population, plus the durat

256 of a biphasic increase, a rapid slope (mean doubling time [t(2)] = 0.5 days) followed by a slower sl

257 When the doubling time (Td) is shorter than the duration of chrom

258 Our study's aim was to quantify tumor doubling time (TDT) and identify correlates associated w

259 The tumor doubling time (TDT), that is, the time to reach twice th

260 ment the growth kinetics of CSCs, population-doubling time, telomere length, telomerase activity, and

261 cells at the old pole attractor had a longer doubling time than ones at the new pole attractor; and (

262 PM II and PM IV/I disruptions have longer doubling times than the 3D7 parental line in rich RPMI m

263 wth from glucose is feasible up to a minimum doubling time that is proportional to the OxPhos burden

264 iscA mutants grew photoautotrophically with doubling times that were similar to the wild type under

265 sufficient for a cell to reproduce measured doubling times, that measured metabolic parameters are n

266 emi-automatically measured volume and volume-doubling time; that national quality assurance boards sh

267 stage of disease at presentation, lymphocyte doubling time, time to first treatment, or progression-f

268 ortant because it would justify using volume doubling time to assess their growth.

269 erefore exists for prostate-specific antigen doubling time to be accepted as a trial endpoint, which

270 re-generated a similar strain and found the doubling time to be twice that of normal cells.

271 sters transmit most of the response of yeast doubling time to galactose; one contains mainly galactos

272 This mutant had comparable doubling times to wild type (WT) in continuous-light-gro

273 is (and other pathogens with relatively long doubling times) to maintain continuous inhibition of ant

274 ate is too slow to account for some observed doubling-time-to-incubation-time ratios inferred from da

275 ling time) and nonaggressive (18-month tumor doubling time) tumors as early as 7.2 months and 8.9 yea

276 graphy (LDCT) screening, expressed as volume-doubling time (VDT), may help to distinguish aggressive

277 e assessed for morphologic change and volume doubling time (VDT), which was calculated by using a mod

278 size at baseline with growth rate and volume doubling time (VDT).

279 APFV doubling time was 6.31 weeks.

280 stay-at-home orders, the median increase in doubling time was 60% (95% CI, 9.2-223.3), compared with

281 The mean doubling time was 856 days for diameter and 285 days for

282 ded on the measurement interval, whereas the doubling time was independent of the interval.

283 Overall, the prostate-specific antigen (PSA) doubling time was observed to increase from a median 6.5

284 rch 2007 in which a PSA dynamic (velocity or doubling time) was calculated in patients before definit

285 Gleason score, PSA level at imaging, and PSA doubling time were 8, 0.42 (interquartile range, 0.29-0.

286 of treatments on endpoint survival and tumor doubling time were analyzed by means of the Kaplan-Meier

287 Changes in cell number and doubling time were insignificant, but cultures exhibited

288 ree MMAE, mutation of cancer genes, and cell doubling time were poorly correlated with in vitro activ

289 Doubling times were available for 38 of 40 patients unde

290 Whereas these doubling times were consistently short and indicated rap

291 Cell population doubling times were determined and correlated with antio

292 earance half-lives and bacterial replication doubling times were estimated using a mathematical model

293 Doubling times were less than 24 mo in 77% (n = 10/13) o

294 The effects on cell doubling times were paralleled by effects on tumorigenic

295 Predicted short and long doubling times were validated on an independent cohort m

296 bstitutions had the same effect on bacterial doubling time when measured at 20 degrees .

297 tcompeted the wild type and exhibited faster doubling times when grown in mucus and on individual com

298 nt recovery of ATPB P:M, ATPase activity and doubling time, whereas Zn and desferrioxamine extended t

299 These cells also exhibited longer population doubling times which did not arise through reduced proli

300 lated into a 2-3-fold increase in tumor cell doubling time without increased apoptosis.